RxDoctor Payments Data

Dennis Verducci, MD

Internal Medicine · Sonoma, CANPI 1437265360

Payments from drug & device makers

$967in general payments, 2019–2025

Across 26 payments — averaging $37.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$504
  • Spineology Inc.$215
  • Regeneron$71
  • Pfizer$47
  • E.r. Squibb & Sons, L.L.C.$35
  • Astellas Pharma US Inc$33
  • plus $62 from 3 others

What the payments were for

  • Food & beverage$967100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$967 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$200,817
Medicare patients
387
Services billed
1,761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$93,632
JardianceEmpagliflozin54$67,594
RybelsusSemaglutide14$22,496
JanuviaSitagliptin Phosphate21$20,817
MyrbetriqMirabegron15$20,461
OzempicSemaglutide17$15,617
Advair HfaFluticasone Propion/Salmeterol15$8,256
Atorvastatin Calcium293$3,610
Losartan Potassium173$2,561
Metoprolol Succinate111$1,839
Levothyroxine Sodium117$1,808
Tamsulosin Hcl73$1,689
Pantoprazole Sodium102$1,637
Amlodipine Besylate159$1,312
Potassium Chloride64$1,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$47$93,632130 claims
Novo NordiskRybelsus, Ozempic$504$38,11331 claims
MerckJanuvia$17$20,81721 claims
Astellas Pharma US IncMyrbetriq$33$20,46115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Sonoma

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →